Amgen announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel. The first randomized clinical trial for a KRASG12C inhibitor assessed the efficacy and safety of LUMAKRAS in 345 previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.
Market Closed -
Other stock markets
|
After market 16:49:25 | |||
307.3 USD | +2.33% | 307.5 | +0.05% |
08:26pm | Mizuho Securities Raises Amgen's Price Target to $235 From $223 | MT |
05-06 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.70% | 161B | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
-1.81% | 157B | |
+3.70% | 124B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Announces Topline Data from LUMAKRAS® Phase 3 Trial in Non-Small Cell Lung Cancer